Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt

Fatty Liver: early-phase trial registry

4 of 21 indexed Fatty Liver trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 4 currently recruiting · #797 of 28,707 conditions by registered trial count

Fatty Liver: 21 US clinical trials tracked, 4 recruiting.

Fatty Liver is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 6 of these trials.

Enrollment posture brief

Registry condition fatty-liver

OPEN 4 | RECR 19% | LATE 1 | EARLY 6 | RANK #797 | SPON 6

Nearest open-share peer: Colonoscopy (19% recruiting · 21 trials)

Anal Cancer42.9%Fatty Liver (this)19%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Fatty Liver

Fatty Liver lists 4 open slots (19% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fatty Liver on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fatty Liver is recruiting below its size-band peers.

    4 of 21 indexed trials (19%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Fatty Liver research.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 6 of 21 trials (28.6%). 16 distinct sponsors appear on at least one study for this condition label.

  3. Most Fatty Liver trials plan to enrol fewer than 100 people.

    Median target enrolment is 54 among the 21 trials that report a genuine target (sentinel values excluded). 14 of those (66.7%) plan for fewer than 100 participants.

  4. Fatty Liver splits between interventional and observational designs.

    13 interventional and 8 observational studies make up this index (61.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 31

Open and recent trials

21 total, page 1 of 1

RECRUITING 1,500 participants

Early Tracking of Childhood Health Determinants (ETCHED) Study

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT03481829

RECRUITING 1,000 participants

Blood Collection Biorepository for Liver Disease Research

State University of New York at Buffalo

NCT03025074

RECRUITING 300 participants

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

Methodist Health System

NCT06225193

RECRUITING NA 25 participants

Intermittent Fasting for NAFLD in Adults

Massachusetts General Hospital

NCT04899102

ACTIVE NOT RECRUITING Phase 2 219 participants

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Rivus Pharmaceuticals

NCT05979779

COMPLETED 400 participants

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy

Brooke Army Medical Center

NCT01100398

COMPLETED Phase 3 173 participants

Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00063635

COMPLETED NA 111 participants

Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

Elysium Health

NCT03513523

COMPLETED 74 participants

Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT02363309

COMPLETED NA 60 participants

Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol

The Cleveland Clinic

NCT01817491

COMPLETED NA 56 participants

Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease

San Antonio Military Medical Center

NCT00815009

COMPLETED 54 participants

Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet

Virginia Commonwealth University

NCT03141008

COMPLETED 53 participants

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT02520609

COMPLETED Phase 1 50 participants

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00862433

COMPLETED Phase 2 37 participants

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00323414

COMPLETED NA 26 participants

Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults

Columbia University

NCT02347007

COMPLETED NA 22 participants

Relation of Obesity With Frequency of Meals (MST 0557)

Rockefeller University

NCT00229255

COMPLETED 22 participants

Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway

University of Texas Southwestern Medical Center

NCT03480594

COMPLETED Phase 2 21 participants

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

Pinnacle Clinical Research, P

NCT03656068

COMPLETED Early Phase 1 9 participants

Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease

Washington University School of Medicine

NCT00949403

COMPLETED Phase 1 5 participants

Study of Gemcabene in Adults With FPLD

Elif Oral

NCT03508687

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Fatty Liver records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Group 3 Placebo Other
1 trials
Group 2 NRPT Dietary supplement
1 trials
Group 1 NRPT Dietary supplement
1 trials
possible liver biopsy and serum collection Procedure
1 trials
600mg Gemcabene Drug
1 trials
300mg Gemcabene Drug
1 trials
Reduced Fat Vegan Diet Other
1 trials
American Heart Association Diet Other
1 trials

US sites by state

Facility locations filed on Fatty Liver trials. A trial with sites in several states counts in each.

Texas 7 trials
Maryland 4 trials
Ohio 3 trials
New York 3 trials
Virginia 2 trials
Missouri 2 trials
Florida 2 trials
California 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fatty Liver page

21 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fatty Liver condition card totals 21 registered trials; most-linked intervention Group 3 Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.